Pentraxin-4: A Potential Drug Target and Biomarker for Inflammation and Chronic Diseases

Target Name: PTX4

NCBI ID: G390667

PTX4

Pentraxin-4: A Potential Drug Target and Biomarker for Inflammation and Chronic Diseases

Pentraxin-4 (ISOform 2) is a protein that is expressed in various cell types in the body. It is a member of the pentraxin family, which includes proteins that are involved in inflammation and immune responses. Pentraxin-4 is a potential drug target or biomarker because of its role in several diseases, including sepsis, Chronic Obstructive Pulmonary Disease (COPD), and Chronic Kidney Disease.

Pentraxin-4 and Inflammation

Pentraxin-4 is involved in the regulation of inflammation and immune responses. It has been shown to play a role in the development and progression of several types of inflammation, including sepsis and chronic obstructive pulmonary disease (COPD).

Sepsis is a life-threatening condition that occurs when the body's response to an infection becomes uncontrolled and causes widespread inflammation. Pentraxin-4 has been shown to be involved in the development and progression of sepsis by promoting the production of pro-inflammatory cytokines and activating immune cells.

In addition to its role in sepsis, pentraxin-4 has also been shown to contribute to the development and progression of COPD. Studies have shown that pentraxin-4 is expressed in the airways of people with COPD and that it is associated with the worsening of COPD symptoms.

Pentraxin-4 and Chronic Kidney Disease

Chronic kidney disease (CKD) is a serious condition that can be caused by a variety of factors, including diabetes, hypertension, and aging. The development and progression of CKD is closely associated with inflammation, and pentraxin-4 has been shown to play a role in this process.

Studies have shown that pentraxin-4 is expressed in the urine and blood of people with CKD and that it is associated with the worsening of kidney function. In addition, pentraxin-4 has also been shown to contribute to the development and progression of acute kidney injury (AKI) in diabetic nephropathy, a common form of diabetes-related kidney disease.

Pentraxin-4 as a Drug Target

The potential use of pentraxin-4 as a drug target or biomarker makes it an attractive target for researchers and pharmaceutical companies. By inhibiting the activity of pentraxin-4, researchers and pharmaceutical companies may be able to develop new treatments for a variety of diseases, including sepsis, COPD, and CKD.

In addition to its potential as a drug target, pentraxin-4 may also be used as a biomarker for several diseases. For example, studies have shown that pentraxin-4 is associated with the severity of sepsis and that it may be a useful biomarker for sepsis. In addition, pentraxin-4 has been shown to be involved in the development and progression of COPD and CKD, making it a potential biomarker for these conditions.

Conclusion

Pentraxin-4 is a protein that is involved in the regulation of inflammation and immune responses. It has been shown to play a role in the development and progression of several types of inflammation, including sepsis and COPD. In addition, pentraxin-4 has also been shown to contribute to the development and progression of CKD.

The potential use of pentraxin-4 as a drug target or biomarker makes it an attractive target for researchers and pharmaceutical companies. By inhibiting the activity of pentraxin-4, researchers and pharmaceutical companies may be able to develop new treatments for a variety of diseases, including sepsis, COPD, and CKD.

Protein Name: Pentraxin 4

The "PTX4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PTX4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets